Alzheimer's disease (AD) is a neurodegenerative disorder with cognitive deficits. Amyloidogenic processing of amyloid precursor protein (APP) produces amyloid b (Ab), the major component of hallmark AD plaques. Synaptic activity stimulates APP cleavage, whereas APP promotes excitatory synaptic transmission, suggesting APP participates in neuronal homeostasis. However, mechanisms linking synaptic activity to APP processing are unclear. Here we show that Polo-like kinase 2 (Plk2), an activityinducible regulator of homeostatic plasticity, directly binds and phosphorylates threonine-668 and serine-675 of APP in vitro and associates with APP in vivo. Plk2 accelerates APP amyloidogenic cleavage by b-secretase at synapses and is required for neuronal overactivity-stimulated Ab secretion. These findings implicate Plk2 as a novel mediator of activity-dependent APP amyloidogenic processing.
Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive deficits accompanied by hallmark neurofibrillary tangles and aggregated amyloid b (Ab) plaques . Aberrant accumulation of Ab may instigate pathogenesis (Hardy and Selkoe, 2002) , based on dominant familial AD (FAD) mutations that increase production or aggregation of Ab (Price and Sisodia, 1998) . Soluble Ab oligomers also block hippocampal long-term potentiation (LTP) and facilitate long-term depression (LTD), prominent models of learning and memory, and induce cognitive impairments in wild-type rodents Shankar et al., 2008; Walsh et al., 2002) . Ab is produced by amyloidogenic processing of amyloid precursor protein (APP) in which APP is initially cleaved by b-secretase (BACE-1), releasing secreted N-terminal sAPPb and a C-terminal fragment (b-CTF) that is subsequently processed by g-secretase to form Ab and APP intracellular domain (AICD). A competing nonamyloidogenic pathway is initiated by a-secretases, producing sAPPa and a-CTF which is also processed by g-secretase (Hardy and Selkoe, 2002) . Despite intense interest in therapeutic manipulation of APP amyloidogenic processing, the physiological mechanism controlling Ab production is still poorly understood.
Increasing evidence suggests that synaptic activity regulates APP processing and AD pathogenesis. Elevated incidence of seizures is observed in AD patients (Palop and Mucke, 2009) , and brain regions with greatest basal metabolic activity, the "default-mode network", exhibit highest amyloid burden in AD (Bero et al., 2011; Buckner et al., 2005) . Furthermore, Ab production is modulated by heightened neuronal activity in vitro and in vivo (Cirrito et al., 2008 (Cirrito et al., , 2005 Kamenetz et al., 2003) , in a stimulus-dependent manner (Hoey et al., 2009; Verges et al., 2011) . While multiple kinases may influence APP metabolism or trafficking, and hyperphosphorylation of APP is observed in human AD brain Schettini et al., 2010) , the precise role of APP phosphorylation and the signaling pathways linking synaptic activity to APP processing remain obscure.
Human Ab soluble oligomers induce synaptic depression via AMPA receptor (AMPAR) removal and dendritic spine loss (Hsieh et al., 2006; Priller et al., 2006) . The finding that Ab production by chronic synaptic overexcitation causes synaptic depression suggests a homeostatic function for Ab at excitatory synapses (Kamenetz et al., 2003) , similar to the known role of Polo-like kinase 2/serum-inducible kinase (Plk2/SNK), an important regulator of homeostatic synaptic plasticity (Seeburg et al., 2005) . Like Ab, Plk2 is also upregulated by hyperexcitation (Kauselmann et al., 1999) to promote synaptic depression, AMPAR internalization, and shrinkage of dendritic spines, whereas Plk3 (the most closely related family member to Plk2 and the only other Plk family member detected in adult brain (Kauselmann et al., 1999) ), is not required for these functions (Evers et al., 2010; Lee et al., 2011; Pak and Sheng, 2003; . These observations suggest a preferential role for Plk2 in homeostatic plasticity and a potential relationship between Plk2 and Ab generation.
Here, we show Plk2 directly binds to and phosphorylates threonine (668) and serine (675) of synaptic APP. Phosphorylation of the two sites is required for activity-inducible APP internalization and amyloidogenic processing, resulting in enhanced Ab production in hippocampal neurons. These findings implicate Plk2 as an important physiological regulator of Ab formation and possibly a target molecule for treatment of AD.
Material and methods

Cell cultures
COS-7 cells were grown in DMEM with 10% fetal bovine serum and 0.1% gentamicin and transfected with 1 mg of DNA using Lipofectamine 2000 (Invitrogen) for 24 h. For cultured neurons, time pregnant Sprague-Dawley rats were purchased from Charles River Laboratories (Wilmington, MA). Wild-type C57BL/6J and APP À/À (B6.129S7-App tm1Dbo /J, stock #004133) mice were purchased from Jackson Laboratory (Bar Harbor, ME). All animal protocols were performed in accordance with guidelines of the Georgetown University Animal Care and Use Committee and the NIH. Hippocampal neurons were prepared from E18 rat embryos and early postnatal (P0eP1) mice (Beaudoin et al., 2012) . Neurons were plated on coverslips coated with poly-D-lysine and laminin and grown in Neurobasal media (Invitrogen) supplemented with B27, 0.5 mM glutamine and 12.5 mM glutamate. Between DIV 20e24, neurons were transfected with 2 mg DNA using Lipofectamine 2000 for 3 days, or infected with Sindbis virus expressing GFP, Plk2-KD, Plk2, APP-WT, or APP-2A for 18 h at high titer to achieve complete infection of the culture. For synaptic overactivity modulation, neurons were treated with 25 mM picrotoxin for 18e20 h.
Antibodies
Rabbit Plk2 antibodies (#7382, ICC (immunocytochemistry) 1:200, IB (immunoblotting) 1:500) used for western blotting and immunoprecipitation and guinea pig SPAR (ICC 1:400) antibodies have been described . The following antibodies were purchased from the indicated suppliers and used at the indicated dilutions: APP-N (Sigma A8967, ICC 1:400, IB 1:1000); RB9023 (Thermo Scientific, ICC 1:5); M3.2 (Biolegend, ICC 1:500); 4G8 (Biolegend, ICC 1:500); APP-C (Sigma A8717, ICC 1:1000); Y188 (OriGene, ICC 1:500, IB:1:1000e1:7000); C1/6.1 (Biolegend, ICC 1:400); sAPPb (Immuno-Biological Laboratories, IB 1:500); 6E10 (Covance, ICC 1:500, IB 1:1000); 22C11 (Millipore, MAB348, IB:1:1000); mouse anti-MAP2 (Sigma, HM-2, ICC 1:400); chicken anti-MAP2 (NeuroMAb, ICC 1:400); Plk2 C-terminal ICC 1:200, IB 1:400) ; GFP (Invitrogen and NeuroMAb, ICC 1:200, IB 1:1000); GluA2 (BD Pharmingen, ICC 1:50e1:100); mouse anti-PSD-95 (NeuroMAb, ICC 1:200); rabbit anti-PSD-95 (Cell Signaling, ICC 1:200); guinea pig anti-Synaptotagmin 1 (Synaptic Systems, ICC 1:500); mouse antiVGlut1 (NeuroMAb, N28/9, ICC 1:200); rabbit anti-HA (Santa Cruz, ICC 1:100); and unlabeled donkey anti-mouse IgG (Sigma). ICC 1:200e400) were secondary antibodies used for immunocytochemistry.
Inhibitors
The following inhibitors were used: b-secretase inhibitor II (BSI, Calbiochem, 1 mM), GM6001 (Calbiochem, 5 mM), TAPI-1 (Calbiochem, 1 mM), DAPT (Calbiochem, 1 mM), BI2536 (Axon MedChem, 50 nM), APV (Tocris Bioscience, 50 mM), CNQX (Tocris Bioscience, 40 mM) or phosphatase inhibitor I and II (Sigma). PTX was freshly prepared as a 10 mM stock in 0.1 M NaOH and used at 25 mM final concentration.
DNA constructs
Myc epitope-tagged Plk2, constitutively active Plk2 (Plk2-CA, T236E), kinase-dead Plk2 (Plk-KD, K108M), human APP770, human APP770 MV (M671V), and phosphorylation site mutants were expressed in pGW1-CMV (British Biotechnology). Oligonucleotides for Plk2 shRNA (Evers et al., 2010; Lee et al., 2011 ) (5 0 -GCA TAG GGA TCT CAA GCT A-3 0 ), rescue constructs (Evers et al., 2010; Lee et al., 2011 ) (5 0 -GCA TAG AGA CCT CAA GCT-3 0 ), and APP shRNA (Hoe et al., 2009 ) (5 0 -GCA CTA ACT TGC ACG ACT A-3 0 ) were inserted into pLL3.7 vector which expresses RNAi-inducing shRNAs and GFP simultaneously under the U6 and CMV promoters. For purified protein production for in vitro binding and kinase assays, the APP Cterminal 47 amino acids were inserted in pMAL-c2x (New England Biolabs) containing maltose binding protein (MBP) with a 73 amino acid multiple cloning site tail. These cloning sites were substituted with the APP C-terminal, leading to a 3 kD decrease in molecular weight of MBP-APPc compared to MBP alone. Plk2 C-terminus including the polo box domain was inserted in pGEX. Site-directed mutagenesis was performed to generate all phosphosite mutants in the hAPP-770 backbone and correct mutations were verified by DNA sequencing (Genewiz). The following oligonucleotides are primer sequences for APP T668 and S675 mutagenesis: hAPP-2A; 5 0 -GAG GTT GAC GCC GCT GTC GCC CCA GAG GAG CGC CAC CTG GCC AAG ATG CAG CAG AAC GGC-3' (sense) and 5 0 -GCC GTT CTG CTG CAT CTT GGC CAG GTG GCG CTC CTC TGG GGC GAC AGC GGC GTC AAC CTC-3 0 (antisense), hAPP-2E; 5 0 -GAG GTT GAC GCC GCT GTC GAA CCA GAG GAG CGC CAC CTG GAA AAG ATG CAG CAG AAC GGC-3' (sense) and 5 0 -GCC GTT CTG CTG CAT CTT TTC CAG GTG GCG CTC CTC TGG TTC GAC AGC GGC GTC AAC CTC-3' (antisense).
Immunoprecipitation and immunoblotting
For immunoprecipitation, cells or tissues were lysed in immunoprecipitation buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% NP40) or RIPA buffer (50 mM Tris pH 7.6, 150 mM NaCl, 1 mM EDTA, 0.5% deoxycholate, 1% NP40, 0.1% SDS) with protease and phosphatase inhibitors (Sigma). After incubation for 20 h at 4 C with 1 mg of antibody and either protein A-Sepharose or protein G-Sepharose, bound proteins were eluted in Laemmli sample buffer and separated by Tris-glycine SDS-PAGE. Proteins were transferred to 0.45 mm pore size nitrocellulose and detected with enhanced chemiluminescence (Pierce) following incubation of HRP-linked secondary antibody. To obtain better resolution and retention of low molecular weight APP-CTF species, protein samples were separated on a 15% Tris-tricine SDS-PAGE gel and transferred to 0.2 mm pore size nitrocellulose.
Immunocytochemistry
For immunolabeling of APP and synaptic markers in primary hippocampal cultured neurons, an optimized fixation protocol for synaptic proteins was used (1% paraformaldehyde for 5 min followed by ice-cold methanol for 7 min), and incubated with primary antibody in GDB buffer (0.1% gelatin (wt/vol), 0.3% Triton X-100 (vol/vol), and 450 mM NaCl in phosphate buffered saline (PBS). Cells were treated with Alexa 488-and Alexa 555-tagged secondary antibody (Invitrogen) in GDB buffer. Transfected neurons were immunolabeled with GFP antibodies to visualize transfected cells. For Sindbis virus experiments, cells were immunolabeled with GFP or Plk2 to visualize infected cells. To detect surface proteins, live labeling was used . Primary hippocampal cultured neurons were incubated with primary antibody in conditioned media at 37 C for 10 min, and fixed with 4% paraformaldehyde for 4 min. Cells were immunolabeled with the fluorescence-tagged secondary antibody in non-permeable condition (ADB buffer, 3% normal goat serum, 0.1% bovine serum albumin in PBS). For further detection of transfected GFP signal, neurons were permeabilized with cold methanol and immunolabeled with GFP followed by the fluorescence-tagged secondary antibody in GDB buffer.
Surface biotinylation
Hippocampal neurons (DIV 20e24) were infected with Sindbis-APP-WT or -2A, and treated with PTX for 18 h. Neurons were washed twice with PBS supplemented with 0.5 mM MgCl and 1 mM CaCl (sPBS), followed by biotinylation reaction (EZ-Link Sulfo-NHS-SS-Biotin, Pierce, 1 mg/ml in sPBS) for 12 min at 4 C with gentle agitation. After biotinylation, cells were washed three times with quenching solution (50 mM glycine and 0.5% BSA in sPBS) and two times with sPBS. Lysates were collected with RIPA buffer with protease inhibitors. A 10% aliquot of the lysates were reserved for total protein fraction, then avidin slurry (NeutrAvidin Agarose Resin, Pierce) was added and rotated for 2 h at 4 C. Beads were washed with RIPA buffer and then biotinylated proteins were eluted in Laemmli sample buffer and resolved by SDS-PAGE. All steps were carried out on ice with cold solutions to prevent trafficking of membrane proteins during biotinylation.
In vitro binding and kinase assay
Bacterially purified MBP-APPc was incubated with GST alone or GST-Plk2c and proteins pulled down with glutathione sepharose resin for immunoblotting with APP C-terminus and GST antibody. For in vitro kinase reactions, MBP-APPc was incubated in 50 mM Tris pH 7.5, 10 mM MgCl 2 , 5 mM DTT and 2 mM EGTA with calf intestine phosphatase (Promega) at 37 C. After 30 min of dephosphorylation, 200 ng of recombinant GST-tagged full-length wild-type Plk2 (Active Motif), 200 mM ATP and phosphatase inhibitor were added, incubated 30 min at 30 C, and then analyzed by immunoblotting with phosphothreonine and APP C-terminus antibodies. For some in vitro kinase assays, full-length myc-hAPP-WT or myc-hAPP-2A was immunoprecipitated from COS-7 cell lysates with antibody 6E10, or with nonimmune mouse IgG, and incubated with recombinant Plk2 as above except with the inclusion of 10 mCi 32 P-g-ATP (Perkin Elmer). Reaction products were examined by immunoblotting with myc antibodies and by autoradiography of SDS-PAGE gels.
Surface plasmon resonance
Assays were performed on a Biacore T-200 instrument in the Georgetown Biacore Molecular Interactions Shared Resource of Lombardi Comprehensive Cancer Center. Response unit (RU) was captured using 5842 RU of ligand. Bacterially purified MBP-APPc, GST-Plk2c and negative control proteins MBP and GST were immobilized on CM5 chips by amine coupling method. 510 RU of GST, 1041 RU of GST-Plk2c, 956 RU of MBP-APPc and 989 RU of MBP were immobilized on Fc1, Fc2, Fc3 and Fc4 respectively. GST-Plk2c and GST proteins were immobilized in 10 mM acetate at pH 4.0; MBP and MBP-APPc were immobilized in 10 mM acetate at pH 4.5. For immobilization steps HBS-P (10 mM HEPES, pH 7.4, 150 mM NaCl, 0.05% P-20) was used as the background running buffer at 10 ml/min flow rate. For binding experiments buffer was switched to a kinase reaction buffer (25 mM Tris pH 7.5, 5 mM MgCl 2 , 2.5 nM DTT, 1 mM EGTA) at 100 ml/min flow rate. MBP-APPc and MBP were injected on flow cells Fc1 and Fc2 with the concentrations 1 mM, 0.5 mM, 0.25 mM, 0.125 mM, 0.0625 mM, 0.0313 mM, and 0 mM (only data for 1 mM shown). The surface was regenerated with 1 M NaCl after each injection. Proteins were injected at 0 s, and 60 s after complex formation, injection was stopped and wash buffer applied. To control for nonspecific binding, the specific signal (Fc2-1) was calculated by subtracting empty buffer and the binding to GST alone (Fc1) from binding to target protein, Plk2c (Fc2). Injections were done in duplicates at least 4 different times, which had similar results.
Ab ELISA
Culture media from hippocampal neurons infected with Sindbis virus expressing human APP were collected after PTX stimulation and BI2536 treatment. N2a cell media were collected 24h after vector or Plk2 transfection. Collected media were analyzed for human Ab40 and Ab42 using species-specific sandwich ELISA (Invitrogen) as described .
Measurement of cell viability
Hippocampal neurons were cultured on 12-well plates at a density of 3 Â 10 5 per well. Viability of cells was measured by incubation for 1 h at 37 C with 0.2 mg/ml of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, Sigma, M2128) dissolved in culture media. The formation of the formazan product, which is proportional to the number of viable cells, was extracted by DMSO and the absorbance was read by a spectrophotometer at 570 nm.
Fluorescence internalization assay
Hippocampal neurons at 21 DIV were co-transfected using Lipofectamine 2000 with hAPP-770 and either empty vector GW1 or HA-Plk2-GW1. Following transfection, live neurons were incubated for 16 h with 6E10 antibody (which recognizes an extracellular epitope on human APP) to allow for surface labeling and internalization. Neurons were then lightly fixed in 2% paraformaldehyde/4% sucrose/PBS for 5 min at room temperature under nonpermeabilizing conditions, washed in PBS, and incubated overnight at 4 C also under nonpermeabilizing conditions with saturating concentration of unlabeled secondary donkey antimouse IgG (100 mg/ml) to mask remaining surface 6E10 antibodies. Neurons were again lightly fixed in 2% paraformaldehyde/ 4% sucrose/PBS for 5 min at room temperature under nonpermeabilizing conditions, washed in PBS, permeabilized in 0.3% Triton X-100, and incubated overnight at 4 C in GDB buffer with rabbit anti-HA antibody to detect Plk2. Some samples were left unpermeabilized by withholding detergent in the buffer for all incubations. Lastly, neurons were incubated in anti-mouse Alexa Fluor 555 to detect internalized 6E10 antibody, and anti-rabbit Alexa Fluor 488 to detect cytoplasmic HA-Plk2.
Quantification and image analysis
Images were obtained using Axiovert 200M (Zeiss) epifluorescence for cultured neurons. Metamorph and ImageJ software was using for image analysis. From culture neuron immunocytochemistry, integrated intensity was measured in 20e30 mm dendritic segments from proximal regions (within 40 mm distance from soma) using Metamorph software.
Statistical analysis
All values were expressed as mean ± SEM of at least duplicate experiments. Sample number represents the number of neurons, cells, or independent cultures as indicated in the figure legends. For analysis of immunofluorescent intensity in cultured hippocampal neurons, 3 dendritic segments from each neuron were measured and averaged per neuron. Two-tailed unpaired Student's t-tests were used for comparisons between two independent groups, and one-way analysis of variance (ANOVA) was used for multiple group comparisons with Tukey's post hoc test. Statistically significant differences were determined at P < 0.05. All image quantification was performed blind with respect to experimental condition to avoid sampling bias.
Results
Synaptic APP displays distinct epitopes
We hypothesized that neuronal activity promotes amyloidogenic processing selectively of synaptic APP. However, APP localization at synapses is controversial, as some groups observed highly synaptic APP distribution (Hoe et al., 2009; Hoey et al., 2009 ) but others showed that several APP antibodies were apparently nonspecific for immunocytochemistry (Guo et al., 2012) . To more thoroughly investigate immunostaining specificity of APP antibodies, we examined a panel of 7 anti-rodent APP antibodies directed against N-terminal (A8967 and RB9023), Ab-site (M3.2 and 4G8), and C-terminal (Y188, A8717, and C1/6.1) epitopes (Fig. 1a ). All antibodies were tested against primary hippocampal neurons cultured from wild-type (WT) mice, as well as from APP knockout (KO) mice as an essential specificity control.
Interestingly, we found that both N-terminal antibodies (A8967 and RB9023) reproducibly showed punctate APP staining that colocalized highly with the excitatory postsynaptic marker PSD-95, but not with the presynaptic markers Synaptotagmin 1 or VGlut1 (Fig. 1b and Supplementary Fig. 1a ,b) (focusing specifically on distal dendrite synapses at high magnification and using fixation conditions and image acquisition settings optimized for detecting synaptic proteins; see Methods). These APP puncta also co-localized extensively with postsynaptic SPAR and AMPAR subunit GluA2 ( Supplementary Fig. 1c) . In striking contrast, the APP Ab-site (Fig. 1c) and C-terminal (Fig. 1d) antibodies showed punctate and granular staining that was entirely excluded from excitatory synapses (i.e., completely non-overlapping with PSD-95). Furthermore, the APP-N (A8967) signals showed negligible co-localization with APP-C (C1/6.1) or with dendritic MAP2, while the APP-C signal was entirely colocalized with MAP2 within dendritic shafts ( Supplementary Fig. 1b) .
Importantly, dendritic and synaptic staining for all 7 antibodies was abolished in APP KO cultured neurons (Fig. 1bed) , indicating that these antibodies are indeed specific and recognize bona fide APP with differential localization patterns. We did observe some weak diffuse staining in KO neurons, but this background was largely restricted to the soma (data not shown). We further verified antibody specificity against APP KO brain lysates as well as cultured neurons in which APP expression was suppressed by previously characterized shRNA (Hoe et al., 2009) (Supplementary Fig. 2 ). We conclude that APP displays distinct epitopes at post-synapses compared to other subcellular locations (Fig. 1e) .
Plk2 is required for activity-induced synaptic APP depletion
Having validated APP synaptic localization and immunocytochemistry specificity, we were able to examine the effect of heightened neuronal activity selectively on synaptic APP. We stimulated cultured hippocampal neurons with GABAA receptor antagonist picrotoxin (PTX), which increases Ab levels in organotypic hippocampal slices (Kamenetz et al., 2003) and in vivo (Bero et al., 2011; Cirrito et al., 2008) . Immunolabeling with APP-N antibodies revealed that APP was markedly downregulated after PTX stimulation when quantifying all APP signal ( Fig. 2a and b) or only postsynaptic APP pixels overlapping with PSD-95 ( Supplementary  Fig. 3 ). This reduction began after 8 h and reached steady-state level by 12 h, with somatic APP decreasing in parallel (Supplementary Figs. 4aed ). APP loss was dose-dependent, plateauing at 20 mM PTX (Supplementary Fig. 4e ). Activation of ionotropic glutamate receptors mediated PTX-induced Plk2 expression (Pak and Sheng, 2003) . Indeed, a combination of APV and CNQX (NMDA and AMPA receptor antagonists, respectively) blocked APP reduction by PTX, but the inhibitors by themselves did not have an effect on APP levels. This result suggests that NMDA and AMPA receptors are involved in APP processing, possibly through Plk2 upregulation ( Supplementary Figs. 5aec) . Thus, chronic neuronal hyperactivity removes synaptic APP with a slow time course suggestive of homeostatic plasticity mechanisms, and the extent of APP loss is related to the degree of overexcitation imposed.
To test whether synaptic APP loss was due to amyloidogenic processing, we applied b-secretase inhibitor (BSI) and found that this treatment blocked the removal of synaptic APP following PTX ( Fig. 2a and b and Supplementary Fig. 3c ), whereas two different asecretase inhibitors (GM6001 and TAPI-1) or g-secretase inhibitor (GSI) failed to restore APP with PTX stimulation ( Supplementary  Fig. 5del ). APP removal was also not due to excitotoxicity, as PTX did not affect dendritic morphology, MAP2 levels, cell viability ( Supplementary Fig. 6 ), or b-actin levels (data not shown). Moreover, APP depletion was unlikely to be simply secondary to postsynapse elimination because co-treatment of PTX with either GSI or BSI blocked loss of PSD-95 that normally occurs with enhanced activity Pak and Sheng, 2003) (Supplementary  Fig. 7 ). BSI or GSI by themselves had no effect on PSD-95 levels. Thus, heightened neuronal activity decreases APP synaptic content specifically in a b-secretase-dependent manner, while loss of PSD-95 requires both b-and g-secretase activities.
Since PTX strongly induces endogenous Plk2 expression (Evers et al., 2010; Lee et al., 2011; Pak and Sheng, 2003; , we used BI2536, a Plk inhibitor (Steegmaier et al., 2007) , to evaluate the role of Plk2 in the above APP loss. When co-applied with PTX stimulation, BI2536 abolished downregulation of synaptic APP levels by hyperactivity (Fig. 2c and d and Supplementary  Figs. 3a and b) . Because BI2536 antagonizes all Plk family members, we also specifically knocked down Plk2 using previously validated shRNA (Evers et al., 2010; Lee et al., 2011) . This manipulation similarly prevented APP removal by PTX, whereas co- for vector þ PTX, 10 for shRNA, 18 for shRNA þ PTX, 7 for Plk2 shRNA þ rescue, 7 for Plk2 shRNA þ rescue þ PTX, 11 for GFP NT, 9 for GFP þ PTX, 7 for Plk2 KD, 7 for Plk2 KD þ PTX).
(g) Neurons were transfected with GFP or Plk2-WT, treated with BSI II (1 mM, 20 h) or vehicle (DMSO), and immunolabeled for GFP or Plk2 and APP N-terminus. (h) Quantification of g (n ¼ 32 neurons for GFP þ vehicle, 16 for GFP þ BSI, 11 for Plk2þvehicle, 9 for Plk2þBSI). ****P < 0.0001; ***P < 0.001; **P < 0.01, *P < 0.05; ANOVA with Tukey's post hoc test. Data are means ± SEM. Experiments were performed in at least duplicate. Scale bars, 10 mm.
transfection of Plk2 shRNA with an shRNA-insensitive Plk2 rescue construct reduced APP intensity by itself and occluded further effect of overactivity ( Fig. 2e and f) . Moreover, APP reduction by PTX was abrogated in neurons transfected with a kinase-dead (KD) Plk2 mutant ( Fig. 2e and f ) that functions in a dominant negative manner in vitro and in vivo . Conversely, overexpression of wild-type (WT) Plk2 was sufficient to remove APP without synaptic activity modulation, which was also prevented by BSI ( Fig. 2g and h ). Taken together, these results suggest that Plk2 kinase function links overactivity to b-secretasemediated reduction in synaptic APP. We further examined the Plk2-APP relationship in COS-7 cells. Co-transfection of WT or constitutively active (CA) Plk2 with human APP (hAPP) caused loss of hAPP protein, as visualized by immunostaining and immunoblotting, whereas Plk2-KD appeared to roughly colocalize with and "protect" hAPP, boosting its expression above control level (Supplementary Figs. 8aed ). These effects were blocked by BSI but not by a-secretase inhibitor GM6001
( Supplementary Figs. 8c and d) . Accordingly, neither Plk2-CA nor Plk2-KD had any discernible effect on levels of hAPP-MV (Kamenetz et al., 2003) 
Plk2 increases APP b-processing
To confirm that Plk2 promotes APP amyloidogenic processing, we analyzed endogenous APP cleavage products (De Strooper and Annaert, 2000) (Fig. 3a) in hippocampal neurons. Compared to control GFP-Sindbis virus-infected hippocampal neurons, cells expressing Plk2-WT-Sindbis virus showed decreased full-length APP and increased sAPPb levels; sAPPb level in cells expressing Plk2-WT was also significantly greater than in cells expressing Plk2-KD (Fig. 3bed) . Furthermore, the b-CTF/a-CTF ratio, an indicator of amyloidogenic APP processing by b-secretase, was enhanced by PTX treatment, while co-treatment of PTX with BI2536 blocked this increase and BI2536 by itself did not have any effect on this ratio ( Fig. 3e and f) . To assay human Ab (hAb) formation, we virally expressed Sindbis-hAPP in hippocampal neurons ( Fig. 3g and h ). PTX stimulation increased levels of hAb40, although there was no significant change in hAb42. BI2536 had no effect by itself, but importantly abolished PTX-induced hAb generation (Fig. 3h) .
To examine the effect of Plk2 on APP-Swe, an FAD mutant that is a superior substrate for BACE-1 versus APP-WT (Price and Sisodia, 1998), we used N2a cells stably expressing hAPP770-Swe (Thinakaran et al., 1996) . Plk2-WT or Plk2-CA transfection, but not Plk2-KD, increased hAb40 in culture media compared to vector control ( Fig. 3i and j) . Thus, Plk2 may act on a central regulatory step upstream of BACE-1 common to rodent and human APP, as well as WT and FAD forms.
Robust and direct interaction of Plk2 and APP
Based on the above findings, we tested whether Plk2 formed a physical complex with APP. First, we observed coimmunoprecipitation (IP) of Plk2-KD and hAPP from COS-7 cells using hAPP-specific 6E10 antibodies but not nonimmune IgG (Fig. 4a) . Interaction experiments in heterologous cells required Plk2-KD to avoid active kinase-dependent loss of APP as shown above. In addition, endogenous APP was co-precipitated with Plk2 in cortical neurons infected with Sindbis-Plk2-KD (Fig. 4b) . This interaction was also confirmed in hippocampal neurons in which the co-IP of endogenous Plk2 and APP was detected in both directions (Fig. 4c) . Moreover, APP was recovered from brain lysates of APP-SwDI transgenic AD mice (Davis et al., 2004) using two independent Plk2 antibodies (Fig. 4d) . Finally, we performed co-IPs from WT mouse brain to confirm endogenous APP and Plk2 association (Fig. 4e) . Crucially, we observed no APP expression or interaction with Plk2 from APP-KO mouse brain (Fig. 4e) , confirming that the in vivo association was specific and genuine. We noted that Plk2 antibody H-90 recovered a much greater fraction of Plk2 than of APP relative to total inputs (Fig. 4c) . This finding suggests that a minor fraction of APP is associated with Plk2, similar to other Plk2 substrates . Interestingly, however, APP antibody Y188 pulled down roughly similar fractions of both APP and Plk2 relative to total inputs (Fig. 4c,e) . Although these immunoblotting data are not linearly quantitative, we infer that a substantial proportion of Plk2 is associated with APP endogenously.
Because co-immunoprecipitation cannot determine whether Plk2 and APP interact directly, we performed in vitro binding assays using purified maltose binding protein (MBP)-tagged APP cytosolic C-terminus (APPc) mixed with GST-tagged Plk2 C-terminus (Plk2c) containing the conserved "polo box domain" important for substrate interactions (Elia et al., 2003) (Fig. 4f) . GST pulldowns demonstrated that MBP-APPc co-purified with GST-Plk2c, but not with the negative control GST alone, indicating direct interaction of Plk2 and APP (Fig. 4g) . Surface plasmon resonance, an independent method to assess direct binding, confirmed that MBP-APPc bound with GST-Plk2c (Fig. 4h) . As controls for nonspecific binding, MBPAPPc failed to bind GST alone, and GST-Plk2 showed no binding to MBP alone (see Methods). Thus, the C-termini of APP and Plk2 interact directly in the absence of other proteins.
Phosphorylation of APP by Plk2
Direct binding implied that Plk2, a serine-threonine (S/T) kinase, may phosphorylate the intracellular tail of APP (Fig. 5a) . Indeed, alanine replacement of all 5 S/T sites in the C-terminus of fulllength hAPP (termed 5A mutant) conferred insensitivity to Plk2 co-expression in COS-7 cells as well as to PTX hyperexcitation in hippocampal neurons (Supplementary Figs. 9aed) . However, mutagenesis of any individual S/T site to alanine had no effect ( Supplementary Figs. 9e and f) . Thus, multiple putative S/T phosphosites seemed required for Plk2-and activity-induced APP bprocessing.
Narrowing candidate residues further, a 4A mutant with alanine replacement of 4 known human AD-associated S/T phosphoresidues was found to be resistant to Plk2, as was triple mutant 3A-2 (T668A/S675A/T686A), whereas a different triple mutant 3A-1 remained sensitive ( Supplementary Figs. 9g and  h ). Among the possible combinations of double mutants derived from 3A-2, only one (T668A/S675A; termed 2A mutant) was blocked from Plk2-mediated processing in COS-7 cells (Fig. 5b and  c) .
To test if T668/S675 were phosphorylated by Plk2, we conducted in vitro kinase reactions with purified APPc domain and fulllength Plk2. Immunoblotting of reaction samples with phosphothreonine antibody revealed autophosphorylated Plk2 as shown previously as well as phosphorylated APPc-WT, but not APPc-2A (Fig. 5d) , indicating direct phosphorylation of APP by Plk2 at T668. Plk2 also phosphorylated full-length immunopurified hAPP in vitro, and this phosphorylation was reduced with the hAPP-2A mutant (34.49 ± 7.6% of hAPP-WT measured by quantitative autoradiography, normalized to total input protein), consistent with phosphorylation of the 2A sites as well as an additional site by (Fig. 5e) . These results suggest that Plk2 directly phosphorylates T668/S675 to control APP amyloidogenic processing.
Plk2 phosphosites regulate surface APP expression
Because neuronal activity-dependent APP b-processing occurs mainly in endosomes (Cirrito et al., 2008) , we examined whether Plk2 mediated-APP phosphorylation regulates its surface expression and internalization. Hippocampal neurons were transfected with hAPP-WT, hAPP-2A, or hAPP-2E (phosphomimic mutant with dual glutamate replacement of T668/S675). Under basal conditions, surface levels of hAPP-2A and hAPP-2E were greater and lower, respectively, than hAPP-WT (Fig. 6aed) , despite similar total expression (Fig. 6eeh) . Moreover, PTX stimulation induced loss of surface and total hAPP-WT, similar to endogenous rat APP, but not hAPP-2A (Fig. 6a,c,e,g ). Surface biotinylation assays independently confirmed that total and surface hAPP-WT, but not hAPP-2A, were diminished by PTX (Fig. 6i and j) . Finally, we demonstrated that Plk2 enhanced the endocytosis of hAPP using an antibody-feeding fluorescence internalization assay (Fig. 6k,l) . These findings suggest that phosphorylation status of T668/S675 bidirectionally regulates APP surface residence.
Conclusions and discussion
We elucidated a critical role for Plk2 in synaptic activitydependent APP metabolism. Plk2 was necessary and sufficient to induce BACE-1-mediated APP amyloidogenic processing following overexcitation, associated intimately with APP, and directly phosphorylated the APP C-terminus. These results establish Plk2 as a previously unknown molecular linkage between neuronal activity and Ab production.
Our study also provides evidence that endogenous APP resides at excitatory synapses, consistent with previous immunocytochemical studies (Hoe et al., 2009; Hoey et al., 2009 ). This finding has been controversial as another group found that several APP antibodies showed lack of specificity and generated high background in APP KO hippocampal neurons (Guo et al., 2012) . However, this analysis did not specifically examine synapses, images were taken at low magnification, and fixation conditions were not optimized for synaptic staining, so no conclusions could be drawn from their study regarding APP synaptic localization. Under our experimental conditions, APP staining in dendrites and synapses with 7 different APP antibodies was absent in APP KO cultures, validating antibody specificity and demonstrating that these antibodies do not give high background when immunostaining is conducted appropriately for synapses. Surprisingly, endogenous APP was detected by rodent antibodies against distinct epitopes in different loci. APP N-terminal antibodies (A8967 and RB9023) recognized postsynaptic APP, but antibodies recognizing Ab sites (M3.2 and 4G8) and C-terminus (A8717, Y188, and C1/6.1) did not. Our interpretation is that various APP epitopes are unmasked at different subcellular locations. Nterminal epitopes seem available only at postsynapses, while Cterminal/Ab ones are exposed only within dendrites. C-terminal and Ab site antibodies may detect different pools of APP as well, such as trafficking full-length APP or intracellular APP processing fragments that lack N-terminal sequences (Fig. 1e ). The precise subsynaptic localization of different APP puncta will be interesting for future analysis using higher resolution methods. We conclude that endogenous APP at synapses is detectable only with N-terminal antibodies, possibly explaining inconsistencies in the field regarding synaptic distribution of APP as results would depend on the particular antibody employed. These data support the general idea that different epitope "fingerprints" of APP are associated with various subcellular locations (presynaptic, postsynaptic, dendritic), suggestive of context-specific conformation or assemblies of protein-protein interactions at these sites. Our results also provide a useful resource for exploiting various epitopes to examine different clusters of APP selectively at specific subcellular loci.
An important mechanistic insight presented here was the identification of both T668 and S675 as essential residues for Plk2-and activity-mediated APP surface loss and processing during heightened synaptic activity. T668 of APP has previously garnered attention as a phosphosite that may stimulate amyloidogenic processing Pastorino et al., 2006) . However, these results are controversial as a T668A knock-in mouse mutation failed to affect constitutive rodent Ab levels although activityinducible formation was not measured (Barbagallo et al., 2010; Sano et al., 2006) . The lack of effect of the T668A knock-in mutation is indeed consistent with and predicted from our findings that showed no effect of the single T668A mutation on activitydependent APP processing. Thus, a single T668A mutation is not sufficient, but requires the additional S675A mutation to block activity-inducible amyloidogenic APP processing. Like T668, S675 is phosphorylated in AD brain , but this site has not been well characterized and does not lie within recognized functional motifs. Further analysis of the molecular function of this phosphorylation site is therefore warranted. In general, multiple APP phosphosites may be differentially recruited in a combinatorial fashion, imparting greater versatility to accommodate APP functions in varied physiological contexts (Hoe et al., 2012) .
We further observed that Plk2 robustly promotes APP internalization. As the APP C-terminus interacts with multiple cytoplasmic adaptor proteins in a phosphorylation-dependent manner (Schettini et al., 2010) , T668/S675 phosphorylation may alter the conformation of this domain, potentially controlling accessibility of internalization or scaffolding motifs. This interpretation is supported by the increased basal surface expression of APP-2A and its inability to undergo surface removal with sustained overactivity. Since endocytosis of APP is considered a prerequisite for amyloidogenic cleavage (Cirrito et al., 2008) and internalized APP is known to sort into BACE-1-containing endosomes upon activity induction (Das et al., 2013) , we surmise that Plk2-dependent internalization of APP could increase its availability for BACE-1 during activity-dependent APP b-processing.
Several additional kinases have been implicated in APP processing (Schettini et al., 2010) such as glycogen synthase kinase-3a (GSK-3a) (Phiel et al., 2003) , although these findings are also controversial (Jaworski et al., 2011) . Contradictory findings may arise because appropriate physiological contexts have not been adequately considered. For instance, Plk2 was required specifically g-secretase inhibitor (DAPT, 1 mm) 30 min prior to stimulation in order to prevent CTF degradation, which confirms the specificity of b-and a-CTF bands (note absence of CTFs without DAPT). (f) Quantification b-/a-CTF ratio from e (n ¼ 5 cultures). (g) Neurons were uninfected or infected with Sindbis-hAPP770 or GFP. Human APP was detected by immunoblotting with APP-N antibodies (exogenous hAPP770 appears larger than the dominant endogenous rat APP695 form). (h) Sindbis-hAPP-infected or uninfected neurons were treated with PTX (25 mM, 20 h) or vehicle (NT) and co-treated with BI2536 (50 nM) or vehicle (DMSO). Human Ab40/42 (hAb) were measured in conditioned media by speciesspecific ELISA and normalized against hAPP expression levels from immunoblotting (n ¼ 2 cultures for uninfected, 6 for NT, 6 for BI2536, 5 for PTX, 6 for PTX þ BI2536). (i) N2a-mychAPP-Swe cells were transfected as indicated and lysates analyzed by immunoblotting. (j) Quantification of hAb40 in conditioned media from i (n ¼ 7 cultures for vector, 8 for Plk2-KD, 8 for Plk2-WT, 9 for Plk2-CA). ***P < 0.001, **P < 0.01, *P < 0.05; ANOVA with Tukey's post hoc test. Data are means ± SEM. Experiments were performed in at least duplicate. Molecular weights are kDa. Cropped blots are displayed for clear and concise presentation. Full western blots are shown in Supplementary Fig. 10 .
for hyperactivity-driven amyloidogenic processing, but not constitutive Ab generation. Other kinases and their cognate phosphorylation site(s) may mediate APP processing only under specific conditions: basally, in different cell types, subcellular compartments, or developmental states, or in response to diverse stimuli such as proliferation or stress. Further work will be required to unravel the complex interplay among different kinases in normal APP processing and AD pathogenesis.
Based on the known role of Plk2 as a homeostatic regulator, we propose a model in which Plk2 and APP comprise a homeostatic negative feedback circuit that may normally function to prevent neuronal overexcitation (see graphic abstract; negative feedback loop). Chronic synaptic overactivity induces somatodendritic expression of Plk2, which binds directly to the intracellular tail of APP and phosphorylates T668/S675, stimulating endocytosis of surface APP and subsequent Ab production. This mechanism occurs over a slow time course, concordant with the observation that many forms of homeostatic plasticity occur on relatively slow timescales (reviewed in Queenan et al., 2012) . On a molecular level, this delay may reflect the time required to induce Plk2 expression, Quantification of k (n ¼ 14 for hAPP þ vector and n ¼ 17 for hAPP þ Plk2). ***P < 0.001, **P < 0.01, *P < 0.05; ANOVA with Tukey's post hoc test (except j and l, unpaired Student's ttest). A.U., arbitrary units. Experiments were performed in at least duplicate unless otherwise noted. Data are means ± SEM. Cropped blots are displayed for concise presentation. Full blots are shown in Supplementary Fig. 10 . ~6e12 h . We speculate this response may contribute to negative feedback homeostasis to dampen overactivity, although this possibility requires further investigation. The observation that activity-dependent loss of PSD-95 staining requires beta-secretase and gamma-secretase inhibitors lends support to the idea that APP processing is involved in synaptic homeostasis, a topic of interest for future study.
However, Ab aggregation may subvert the physiological homeostatic system during pathogenesis, yielding plaque-associated hyperexcitability instead (Busche et al., 2008; Minkeviciene et al., 2009; Palop et al., 2007; Rudinskiy et al., 2012) . This situation could create a positive feedback loop (see graphic abstract; positive feedback loop) that produces further aggregates and synaptic overactivity. It will be important to confirm the proposed model in vivo, by testing whether inhibition of Plk2 kinase function prevents Ab production, plaque formation, and memory deficits in AD mouse models.
Notably, Ab and Plk2 are both synaptotoxic and lead to synapse loss, a strong correlate of cognitive decline in AD (Hardy and Selkoe, 2002) . The mechanism described here may present therapeutic opportunities for addressing excess synapse loss and possibly memory impairments in AD by engaging physiological regulatory networks of controlling APP metabolism. 
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